Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sego Intersects 100 M of 0.626 gpt Gold, Including 24.37 M of 0.958 gpt Gold (click to learn more) This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare Biotechnology
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia... see more

Current News (NDAQ:AMLX)

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Business Wire 6 days ago

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Business Wire March 24, 2026

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Business Wire March 3, 2026

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Business Wire February 26, 2026

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Business Wire February 24, 2026

INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigation of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and Encourages Long-Term Amylyx Investors with Losses to Contact the Firm

ACCESS Newswire January 28, 2026

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

Business Wire January 8, 2026

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Business Wire December 5, 2025

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

PR Newswire November 28, 2025
View More News ››

Opinion & Analysis (NDAQ:AMLX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:AMLX)

Buy buddy buy.

Otherwise FOMO anyway,so good luck to all shareholders out there
coolfooldumbguy - June 24, 2025

CAN AMX0035 BE A POTENTIAL GAME CHANGER IN ALS?

  $AMLX   Excited to share an article about Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) that is awaiting regulatory...
AviseAnalytics - March 16, 2022
View more Bullboard ››

Deep Sea Minerals Corp.

Deep Sea Minerals Corp.

Deep Sea Minerals Corp. engages in the exploration and development of deep-sea critical minerals for energy security, defense ...
View More »

Podcasts